Arovella Therapeutics (ASX:ALA) has reported new preclinical data that strengthens the case for its engineered immune cell platform, demonstrating sustained and enhanced killing of pancreatic and gastric cancer cells in laboratory studies. …
Engineered immune cells show striking durability against hard to treat cancers
April 1, 2026 Australian Biotech
Latest Video
New Stories
-
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News